Filing Flows › Comparisons › INO vs AVTX
Inovio Pharmaceuticals vs Avalo Therapeutics: INO and AVTX compared
Inovio Pharmaceuticals is the larger company: $65K of revenue in its latest quarter (Q1 2025) against $59K for Avalo Therapeutics (Q4 2025).
Where the money goes: INO and AVTX
Inovio Pharmaceuticals (INO) · Q1 2025
Inovio Pharmaceuticals, Q1 2025: revenue $65K, net loss $19.7M, operating cash flow −$26.9M. The chart follows the revenue to costs, profit and cash.
Avalo Therapeutics (AVTX) · Q4 2025
Avalo Therapeutics, Q4 2025: revenue $59K (-69% year over year), net loss $13.7M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.
| Inovio Pharmaceuticals (INO) | Avalo Therapeutics (AVTX) | |
|---|---|---|
| Latest quarter | Q1 2025 | Q4 2025 |
| Revenue | $65K | $59K |
| Revenue growth, Y/Y | — | -69% |
| Operating margin | n/m | n/m |
| Net earnings | −$19.7M | −$13.7M |
| Operating cash flow | −$26.9M | −$14.2M |
| Market value | — | $595M |
| Analysts’ mean target | — | $36.60 |
Questions
Which is bigger, Inovio Pharmaceuticals or Avalo Therapeutics?
Inovio Pharmaceuticals is the larger company: $65K of revenue in its latest quarter (Q1 2025) against $59K for Avalo Therapeutics (Q4 2025).
More: Inovio Pharmaceuticals earnings · how Inovio Pharmaceuticals makes money · Avalo Therapeutics earnings · how Avalo Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 13, 2025; 10-K filed Mar 23, 2026). Fiscal quarters can end on different dates. Not investment advice.